Regular Article
Low Doses of EPO Activate MAP Kinases but Not JAK2–STAT5 in Rat Vascular Smooth Muscle Cells

https://doi.org/10.1006/bbrc.2001.5085Get rights and content

Abstract

Previous reports have shown a direct effect of erythropoietin (Epo) on vascular smooth muscle cells (VSMCs). Our aim was to assess expression of the Epo receptor (EpoR) on VSMCs and to study the activation of two major signaling cascades activated by Epo, namely JAK2/STAT5 and MAPK pathways. All experiments were performed in parallel using the Epo-responsive UT7 cell line. From semiquantitative RT-PCR experiments, VSMCs were estimated to express ∼30-fold less EpoR mRNA than UT7 cells. Epo-induced phosphorylation of proteins involved in the EpoR/JAK2/STAT5 cascade could not be detected in VSMCs, even using pharmacological doses of Epo (250 IU/ml). In contrast, a strong activation of MAP kinase pathway was detected with as low as 10 IU/ml Epo. We suggest that MAPK activation reflects a physiologically relevant effect of Epo on VSMCs that may be correlated to cell proliferation.

References (47)

  • S.B. Krantz

    Blood

    (1991)
  • J.W. Adamson et al.

    Am. J. Med.

    (1968)
  • J. Gogusev et al.

    Biochem. Biophys. Res. Commun.

    (1994)
  • J.N. Ihle et al.

    Trends Genet.

    (1995)
  • S.T. Sawyer et al.

    J. Biol. Chem.

    (1996)
  • O. Miura et al.

    Blood

    (1994)
  • B.A. Witthuhn et al.

    Cell

    (1993)
  • C. Pallard et al.

    J. Biol. Chem.

    (1995)
  • F. Amiri et al.

    J. Biol. Chem.

    (1999)
  • O. Hermine et al.

    Blood

    (1992)
  • P. Mayeux et al.

    J. Biol. Chem.

    (1987)
  • T. Akimoto et al.

    Kidney Int.

    (2000)
  • D.M. Wojchowski et al.

    Exp. Cell Res.

    (1999)
  • K. Ishiguro et al.

    Cytokine

    (1998)
  • R. Shimizu et al.

    Exp. Hematol.

    (1999)
  • Y. Miura et al.

    J. Biol. Chem.

    (1994)
  • K. Todokoro et al.

    Biochem. Biophys. Res. Commun.

    (1994)
  • H. Kouchi et al.

    Biochem. Biophys. Res. Commun.

    (1999)
  • D.F. Liao et al.

    J. Biol. Chem.

    (1997)
  • C. Yang et al.

    Cell Signal.

    (2000)
  • S. Heeneman et al.

    J. Biol. Chem.

    (2000)
  • G. Maschio

    Nephrol. Dial. Transplant.

    (1995)
  • A.A. Geisterfer et al.

    Circ. Res.

    (1988)
  • Cited by (51)

    • Erythropoietin and Nonhematopoietic Effects

      2017, American Journal of the Medical Sciences
      Citation Excerpt :

      However, exogenous EPO elicits physiological effects in the normal kidney not primarily associated with tissue protection, and this could have important implications in certain clinical situations.26,34,35 One important EPO target is the vascular smooth muscle cell where EPO increases intracellular calcium and causes contraction of vascular smooth muscle cell in vitro and constriction in vivo, thus significantly increasing peripheral vascular resistance.29,36 Clinically, EPO has variable effects on systemic blood pressure and vascular resistance.

    • EPO gene expression promotes proliferation, migration and invasion via the p38MAPK/AP-1/MMP-9 pathway by p21WAF1 expression in vascular smooth muscle cells

      2015, Cellular Signalling
      Citation Excerpt :

      Several reasons have been suggested for the complicating and proliferative effects of EPO on vascular smooth muscle cells (VSMCs). The EPO treatment-induced proliferation of VSMCs has been documented in several signaling pathways, in phospholipase C (PLC) activity, and in the inhibitory effect of apoptotic action [15–19]. However, the roles and molecular mechanisms of migration, invasion, and cell-cycle regulation in VSMCs in response to EPO are yet to be formally investigated.

    • Experimental acute myocardial infarction in rats: HIF-1α, caspase-3, erythropoietin and erythropoietin receptor expression and the cardioprotective effects of two different erythropoietin doses

      2013, Acta Histochemica
      Citation Excerpt :

      The protective effects of Epo against tissue ischemia are mediated by erythropoietin receptor (EpoR) (Brines et al., 2004). In addition to erythroid progenitor cells, a varied group of cells including neurons, endothelial cells, vascular smooth muscle cells, and cardiac myocytes, express EpoR (Anagnostou et al., 1994; Digicaylioglu et al., 1995; Akimoto et al., 2000; Ogilvie et al., 2000; Ammarguellat et al., 2001; Digicaylioglu and Lipton, 2001; Tramontano et al., 2003; Jelkmann and Wagner, 2004; Marti, 2004). The cardioprotective effects of Epo have become a topical issue after detection of EpoR expression on cardiomyocytes (Marzo et al., 2008).

    View all citing articles on Scopus
    1

    Current address: Clinical Research Institute of Montreal–Experimental Hypertension, 110 Pine Avenue West, Montreal, Québec, Canada H2W 1R7.

    2

    To whom correspondence and reprint requests should be addressed. Fax: 33 1 43.06.04.43. E-mail: [email protected].

    View full text